Anti-L1CAM antibody therapy for rare diseases
People
(Responsible)
Abstract
development of therapeutic antibodies and IOR's expertise in basic and translational research in rare cancer types, we aim to develop a new efficacious immunotherapy for patients suffering from highly aggressive malignancies.
Additional information
Start date
01.11.2020
End date
01.11.2022
Duration
24 Months
Funding sources
Status
Ended
Category
Innosuisse /
Innovation projects
